3 completed, 2 unknown, 1 active not recruiting. 6 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Unknown 2, Active not recruiting 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Unknown 1 |
Follow Polycystic liver disease: new trials by email Literature Review of Polycystic liver disease trials Research Report on Polycystic liver disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD CAM2029, Placebo - Polycystic Liver Disease | Phase 2 / Phase 3 | Active not recruiting | Camurus AB | 71 | 2022-06-28 | 2026-06-01 |
| Study of Lanreotide to Treat Polycystic Kidney Disease Lanreotide - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 3 | Unknown | University Medical Center Groningen | 300 | 2012-06-01 | 2017-05-23 |
| Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease Lanreotide Autogel 90 mg and 120 mg - Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Universitaire Ziekenhuizen KU Leuven | 59 | 2011-03-01 | 2014-07-08 |
| Open-Label Extension of LOCKCYST Trial lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Unknown | Radboud University Medical Center | 54 | 2008-04-01 | 2008-11-13 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| Octreotide in Severe Polycystic Liver Disease Octreotide, Placebo - Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 42 | 2007-01-01 | 2012-11-21 |
Polycystic Kidney, Autosomal Dominant (4) · Hepatomegaly (3) · Liver Diseases (3) · Polycystic Kidney Diseases (3) · Abdominal Pain (1) · Multiple Pterygium Syndrome, Autosomal Dominant (1)
Abnormalities, Multiple (5) · Ciliopathies (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genetic Diseases, Inborn (5) · Kidney Diseases (5) · Kidney Diseases, Cystic (5) · Male Urogenital Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Digestive System Diseases (3) · Hypertrophy (3) · Pathological Conditions, Anatomical (3)
lanreotide (3) · Octreotide (1)
Radboud University Medical Center (2) · Camurus AB (1) · Mayo Clinic (1) · Universitaire Ziekenhuizen KU Leuven (1) · University Medical Center Groningen (1)
Belgium (4) · Netherlands (4) · United States (2) · Germany (1)
Frederik Nevens, MD, PhD (3) · Loes van Keimpema, MSc (2) · Joost Drenth, MD (1) · Joost PH Drenth, MD, PhD (1) · Joost PH Drenth, PhD (1) · Marie C. Hogan, M.D., Ph.D. (1) · Ron Gansevoort, MD, PhD (1)
PMID 39356039, PMID 19646443, PMID 22773240, PMID 26073493, PMID 26166166, PMID 27995519, PMID 30422235, PMID 31022403, PMID 33779943
UL1RR024150 (1)